Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report.
Adefovir dipivoxil
Case report
Fanconi’s syndrome
Osteomalacia
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
05 06 2020
05 06 2020
Historique:
received:
03
12
2019
accepted:
26
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
10
4
2021
Statut:
epublish
Résumé
Progressive bone pain and fracture and abnormal positron emission tomography combined with a computed tomography are main reasons for the oncologists suspecting bone tumor. During the patient's medical treatment, the oncologists' unfamiliarity with adverse reactions to anti-HBV drugs were main reason for the long-term exposure to the drug and the adverse reaction (ADR) experienced by the patient. A 63-year-old Chinese man had a 27-month history of progressive generalized bone pain combined with spontaneous fractures. Positron emission tomography combined with a computed tomography, revealed an abnormal increase in ribose metabolism and low positron serum inorganic phosphorus concentration (0.7; 0.78-1.65 mmol/L). Serum creatinine level was 252 μmol/L (53-97) μmol/L, and glomerular filtration rate was 22.79 mL/min/1.73 m Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day. This case highlights the importance of ADR as a differential diagnosis and the need of pharmacists with drug safety expertise expert in the patient management.
Sections du résumé
BACKGROUND
Progressive bone pain and fracture and abnormal positron emission tomography combined with a computed tomography are main reasons for the oncologists suspecting bone tumor. During the patient's medical treatment, the oncologists' unfamiliarity with adverse reactions to anti-HBV drugs were main reason for the long-term exposure to the drug and the adverse reaction (ADR) experienced by the patient.
CASE PRESENTATION
A 63-year-old Chinese man had a 27-month history of progressive generalized bone pain combined with spontaneous fractures. Positron emission tomography combined with a computed tomography, revealed an abnormal increase in ribose metabolism and low positron serum inorganic phosphorus concentration (0.7; 0.78-1.65 mmol/L). Serum creatinine level was 252 μmol/L (53-97) μmol/L, and glomerular filtration rate was 22.79 mL/min/1.73 m
CONCLUSION
Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day. This case highlights the importance of ADR as a differential diagnosis and the need of pharmacists with drug safety expertise expert in the patient management.
Identifiants
pubmed: 32503675
doi: 10.1186/s40360-020-00421-6
pii: 10.1186/s40360-020-00421-6
pmc: PMC7275610
doi:
Substances chimiques
Antiviral Agents
0
Organophosphonates
0
Adenine
JAC85A2161
adefovir dipivoxil
U6Q8Z01514
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43Références
Kidney Int. 2015 May;87(5):1030-8
pubmed: 25426815
Oncol Lett. 2017 Jan;13(1):307-314
pubmed: 28123560
World J Hepatol. 2010 Dec 27;2(12):442-6
pubmed: 21191520
J Med Case Rep. 2019 Apr 20;13(1):99
pubmed: 31003599
BMC Nephrol. 2017 Aug 29;18(1):275
pubmed: 28851305
J Intern Med. 1990 Aug;228(2):83-90
pubmed: 2394974
Drug Des Devel Ther. 2019 Apr 10;13:1127-1133
pubmed: 31118563
BMJ. 2010 Mar 23;340:c951
pubmed: 20332315
BMC Pharmacol Toxicol. 2018 May 16;19(1):23
pubmed: 29769119
World J Gastroenterol. 2015 Mar 28;21(12):3657-62
pubmed: 25834334
Scand J Infect Dis. 2011 Dec;43(11-12):990-2
pubmed: 21609200
Expert Opin Drug Saf. 2011 Sep;10(5):809-18
pubmed: 21671843
J Clin Pharm Ther. 2013 Aug;38(4):321-6
pubmed: 23590583
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Bone Miner Metab. 2013 Mar;31(2):240-6
pubmed: 22976054
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Gastroenterol Hepatol. 2012 Feb;27(2):306-12
pubmed: 21777281
Nephrol Ther. 2005 Nov;1(5):296-300
pubmed: 16895698
Clin Mol Hepatol. 2017 Sep;24(3):339-344
pubmed: 28859264
Urol Oncol. 2011 Jul-Aug;29(4):378-82
pubmed: 19576797